Fatima et al. demonstrated that ONC212 impairs BCR and BCL-2 signaling, induces ATF4 expression, and disrupts microenvironmental survival cues in CLL cells, including TP53-deficient models, supporting its potential application in lymphoid malignancies [34]. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.